Needle-free drug injection company PharmaJet is close to completing a $5 million fundraising round of financing that would fund the production of 5 million syringes to deliver the polio vaccine.
PharmaJet touted results today from a study evaluating its needle-free injection technology as a way to administer the poliovirus vaccine.
Needle-free injection technology company PharmaJet, based in Golden, Colo., will be working with French biopharma company Invectys to test Invectys’ therapeutic cancer vaccine.
With polio vaccine in short supply, the World Health Organization has tapped a Golden-based medical device startup to help fill the gap.
The award was received for innovation in the Bioscience and Medical arena, honoring PharmaJet’s contribution to advancing the industry and highlighting their contribution to the fight against polio.
PharmaJet’s needle-free injection technology was featured on a CBS 60 Minutes segment concerning the National Institutes of Health DNA vaccine clinical trial for the Zika virus.
Colorado U.S. Senator Michael Bennet today visited PharmaJet in Golden, where the Colorado-based device company is involved in clinical trials with the National Institutes of Health
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection.
Biotech company Inovio creates a Zika vaccines that needs to use needle-free technology.
